Biomarkers

In her Introduction to the special edition of CONQUER titled Understanding Biomarkers & Molecular Testing, Lillie D. Shockney, RN, BS, MAS, ONN-CG, briefly explains what biomarkers are, why they are important, and what you should know about them.   Read More ›

One-size-fits-all medicine is a thing of the past. Cancer, at its core, is a genetic disease. Today’s advances in cancer research mean that doctors can now tailor a personalized treatment to the patient’s specific cancer type. Read More ›

Wenora Y. Johnson, 3-time survivor, shares her cancer story and encourages patients to ask their care team about biomarker testing. Read More ›

This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL). Read More ›

Dr Hayes, Immediate Past President of ASCO and Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center, explains how biomarkers offer more precise treatment opportunities for patients with breast cancer. Read More ›

Read about important advancements in tumor biomarkers and their role in guiding treatment in some types of cancer. Read More ›

In recent years, new treatments for acute myeloid leukemia have improved outcomes. In 2017, 2 new drugs were approved for patients with this type of blood cancer linked to a specific biomarker. Read More ›

The understanding of the role of dMMR or MSI-H biomarkers in cancer has led to the first approval of a cancer drug based on a biomarker instead of a specific tumor type. Read More ›

Biomarkers are biologic markers that indicate changes in our genes and may increase the risk of cancer. Read More ›